ROIVANT SCIENCES LTD. (ROIV) Debt Components
- 2024-06-30: Short-term DebtUSD (m); Long-term Debt, Current MaturitiesUSD $12.00M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $311.72M.
- 2024-03-31: Short-term DebtUSD (m); Long-term Debt, Current MaturitiesUSD $12.00M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $430.59M.
- 2023-12-31: Short-term DebtUSD (m); Long-term Debt, Current MaturitiesUSD $45.71M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $403.34M.
- 2023-09-30: Short-term DebtUSD (m); Long-term Debt, Current MaturitiesUSD $49.00M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $389.44M.
ROIVANT SCIENCES LTD. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Short-term Debt USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Debt Instrument, Fee Amount USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Long-term Debt, Fair Value USD | Debt Instrument, Interest Rate, Stated Percentage pure | Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate pure | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | (m) | $12.00M | (m) | $311.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $82.37M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $12.00M | (m) | $430.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $204.37M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $45.71M | (m) | $403.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $194.56M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $49.00M | (m) | $389.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $188.91M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $44.41M | (m) | $385.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $187.14M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $40.72M | (m) | $375.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $180.70M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $37.72M | (m) | $375.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $183.51M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $35.75M | (m) | $376.06M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $188.68M | (m) | (m) | (m) |
| 2022-06-30 | $33.30M | (m) | (m) | $383.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $200.70M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $0.00 | (m) | $210.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $177.40M | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $210.03M | (m) | $0.00 | $0.00 | $0.00 | $0.00 | $45.00M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | $12.38M |
| 2021-12-31 | (m) | $0.00 | $204.04M | $204.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $211.90M | (m) | $171.90M | (m) | (m) | $12.86M |
| 2021-09-30 | (m) | $0.00 | $199.87M | $199.87M | (m) | (m) | (m) | (m) | (m) | (m) | $4.00M | $208.20M | (m) | $168.20M | (m) | (m) | $13.33M |
| 2021-06-30 | (m) | $0.00 | $186.35M | $186.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $195.20M | (m) | $155.20M | (m) | (m) | $13.85M |
| 2021-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-05-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 10.00% | (m) | (m) |
| 2021-03-31 | (m) | $0.00 | $170.28M | $170.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $150.10M | (m) | (m) | $1.21M |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $170.10M | (m) | (m) | (m) | (m) | (m) |
| 2019-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.40M | (m) | $20.00M | (m) | (m) | 9.95% | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |